13th Annual Scientific Meeting
21 – 23 February, 2017 // The Fairmont, Washington DC
Distinguished Poster Award Recipient:
|
||
| Estimating Treatment Effect Heterogeneity in Cognitive Training Programs (Khan) | ||
|
All Poster PDFs and Abstracts are available at the end of the second day. |
||
Day 1 (21 February 2017) |
||
| Presidential Welcome | S Marder slides video |
|
| Advantages and Challenges of Adaptive CNS Trials: Real World Lessons | Chairs: R Marcus J Kando |
|
| Introduction/Brief update | R Marcus slides video |
|
| Adaptive Population Enrichment Design: Drug Development Efficacy in Rare Epileptic Symptoms | J Segieth slides video |
|
| Adaptive Design Comparative Effectiveness in Status Epilepticus | K Broglio slides video |
|
| Identification of Meaningful Cognitive Endpoints in Studies of Pharmacological Therapies for Cognitive Impairment in Schizophrenia | M Sand slides video |
|
| Layers of an Onion: Considerations for a Confirmatory, Adaptive CNS Trial | B Millen slides |
|
| Update from FDA Statistician on Adaptive Design Methodology | H M Hung* |
|
| Panel Discussion | Speakers video |
|
|
Working Group Dinners |
||
| Abuse Liability: A Lethal Combination: Clinical Trial Design Considerations to Elevate the Nature of Opioid and Benzodiazepine Interactions | Chairs: B Setnik M Sokolowska M Klein Working Group Slides: slides |
|
| Behavioral and Psychiatric Symptoms in Dementia | Chairs: L Ereshefsky D Miller L Pani Working Group Summary: slides |
|
| Prevention Trials of Alzheimer’s Disease- Ongoing Optimization and the Roles of Biomarkers and Cognitive, Performance, and Functional Assessments | Chairs: H Posner P Harvey Working Group Slides: Arrighi Beckett Bilgel |
|
| Cognitive Dysfunction | Chairs: J Parker M Fava Working Group Summary: slides |
|
| Methodological Challenges in International CNS Clinical Trials | Chairs: A Kalali E Pappadopulos Working Group Summary: slides |
|
| Missing Data | Chairs: P Lim N Samad Working Group Summary: slides |
|
| Negative Symptoms | Chairs: S Marder D Daniel Working Group Summary: slides |
|
| Mitigating Nonadherence | Chairs: T Shiovitz D McCann Working Group Summary: slides |
|
Day 2 (22 February 2017) |
||
| Optimizing Use of ‘Big Data’ for Patient Identification and Disease Management: Separating Signal from Noise- Part 1 | Chairs: L Alphs G Wittenberg |
|
| Introduction | L Alphs slides video |
|
| The ‘Big Data’ Transformation of Drug Development: From Promise to Practice | G Wittenberg slides video |
|
| Generating Reliable Evidence from Real-World Data: Lessons from the Observational Health Data Sciences and Informatics (OHDSI) | P Ryan slides video |
|
| A Model of Virtual Learning Health System for Mood Disorders | P Zandi slides video |
|
| Harnessing Mobile and Sensor Technology to Help Patients with Diseases of the Brain and Central Nervous System | V Narayan slides video |
|
| ADNI as a Model of ‘Big Data’ Collaboration | S Potkin slides video |
|
| Data Linkage Methods and Challenges | A Kress slides video |
|
| Panel Discussion | Speakers video |
|
| Optimizing Use of ‘Big Data’ for Patient Identification and Disease Management: Seperating Signal from Noise- Part 2 | Chairs: L Alphs G Wittenberg |
|
| Review of Morning Session | L Alphs video |
|
| Challenges/Opportunities in the use of ‘Big Data’ for the FDA | B Temple slides video |
|
| Regulatory Opportunities and Challenges in Europe: From Registries to PRIority MEdicines (PRIME) and Return | L Pani slides video |
|
| Optimizing Use of ‘Big Data’ for Patient Identification and Disease Management—An Example from the Department of Veterans Affairs | R Bossarte*
|
|
| Challenges/Opportunities in the Use of ‘Big Data’ in Health Care Services Setting (pharmacy/insurer) | A Contreras slides video |
|
| Public Policy Around ‘Big Data’ | A Basu slides video |
|
| Panel Discussion and Open Discussion Summary |
G Wittenberg Speakers video |
|
| Poster Session/Reception | Poster PDFs and Abstracts | |
Day 3 (23 February 2017) |
||
| Presentation of the Andrew C. Leon Distinguished Career Award | S Marder slides L Alphs slides video |
|
| Silver Linings Playbook: The Positive Side of Negative Trials | Chairs: R Keefe S Romano |
|
| Introduction | R Keefe slides video |
|
| “The Set-Up”: Skimping on the Fundamentals Can Lead to Failure | S Romano slides video |
|
| Failures of Translation in Stroke and Cerebrovascular Disease: What Can Be Learned? | D Laskowitz slides video |
|
| The Difficulties in Going from P2 To P3 in CNS Trials: Red Flags from a Recent CIS Program | S Brannan slides video |
|
| How Molecules that Fail can Influence Future Research: Semagacestat and BACE Inhibitors |
R Mohs slides video |
|
| A New PANSS Factor Analysis Intended to Reduce Pseudospecificity Among Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients with Schizophrenia | T Loebel/ S Hopkins* |
|
| Panel and Regulatory Discussion | R Keefe T Laughren L Pani video |
|
| Meeting Adjourned |
S Marder | |
| *Presentation not released | ||